How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/chemotherapy-induced-neutropenia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Chemotherapy-induced neutropenia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chemotherapy-induced neutropenia (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Chemotherapy-induced neutropenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lonquex	LIPEGFILGRASTIM	Sicor Biotech UAB		Granulocyte colony-stimulating factor receptor	2013-01-01
Neulasta	PEGFILGRASTIM	Amgen	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor	2002-01-01
Neulasta	Pegfilgrastim-Apgf	Amgen	Colony-stimulating factor	G-CSF receptor on hematopoietic cells	2002-01-01
Neupogen	Filgrastim-Aafi	Amgen	Colony-stimulating factor (CSF); leukocyte growth factor	G-CSF receptor (granulocyte colony-stimulating factor receptor)	1991-01-01
Leukine	SARGRAMOSTIM	Berlex Labs	Leukocyte Growth Factor [EPC]	Granulocyte macrophage colony-stimulating factor receptor	1991-01-01
Neulasta	Neulasta	Columbia University		Granulocyte colony-stimulating factor receptor
FULPHILA	PEGFILGRASTIM-JMDB	MYLAN GMBH	Leukocyte Growth Factor [EPC]	Granulocyte colony-stimulating factor receptor
Neupogen	Neupogen	University of Chicago		Granulocyte colony-stimulating factor receptor
Leukine	Leukine	University of Kentucky		Granulocyte macrophage colony-stimulating factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Amgen · 3 drugs in Chemotherapy-induced neutropenia
Berlex Labs · 1 drug in Chemotherapy-induced neutropenia
Columbia University · 1 drug in Chemotherapy-induced neutropenia
MYLAN GMBH · 1 drug in Chemotherapy-induced neutropenia
Sicor Biotech UAB · 1 drug in Chemotherapy-induced neutropenia
University of Chicago · 1 drug in Chemotherapy-induced neutropenia
University of Kentucky · 1 drug in Chemotherapy-induced neutropenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Chemotherapy-induced neutropenia:

Cite this brief

Drug Landscape (2026). Chemotherapy-induced neutropenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/chemotherapy-induced-neutropenia. Accessed 2026-06-10.

Chemotherapy-induced neutropenia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing